ChromaDex Corporation (CDXC) Q2 2023 Earnings Call Transcript


ChromaDex Corporation (NASDAQ:CDXC) Q2 2023 Earnings Call Transcript August 9, 2023 4:30 PM ET

Company Participants

Kendall Knysch – Director, Media Relations

Rob Fried – Chief Executive Officer

Brianna Gerber – Chief Financial Officer

Conference Call Participants

Ram Selvaraju – H.C. Wainwright

Jeff Van Sinderen – B. Riley

Mitch Pinheiro – Sturdivant

Sean McGowan – ROTH MKM

Operator

Hello. My name is Aisha and I’ll be your conference operator today. At this time, I’d like to welcome everyone to the ChromaDex Second Quarter 2023 Conference Call. [Operator Instructions].

Thank you. Kendall Knysch, you may begin your conference.

Kendall Knysch

Thank you. Good afternoon and welcome to ChromaDex Corporation’s second quarter 2023 results investor call. With us today are ChromaDex’s Chief Executive Officer, Rob Fried; Chief Financial Officer, Brianna Gerber; and Senior Vice President of Scientific and Regulatory Affairs, Dr. Andrew Shao, who will join in the call for Q&A.

Today’s conference call may include forward-looking statements, including statements related to ChromaDex’s research and development and clinical trial plans and the timing and results of such trials, the timing of future regulatory filings, the expansion of the sale of Tru Niagen in new markets, business development opportunities, future financial results, cash needs, operating performance, investor interest, and business prospects and opportunities, as well as anticipated results of operations.

Forward-looking statements represent only the company’s estimates on the date of this conference call and are not intended to give any assurance as to actual future results. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties.

Many factors could cause ChromaDex’s actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These risk factors include those contained in ChromaDex’s quarterly reports on Form 10-Q most recently filed



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *